TY - JOUR
T1 - BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study
AU - Rijnsburger, Adriana J.
AU - Obdeijn, Inge-Marie A.
AU - Kaas, Reinoutje
AU - Tilanus-Linthorst, Madeleine A.
AU - Boetes, Carla
AU - Loo, Claudette E
AU - Wasser, Martin N. J. M.
AU - Bergers, Elisabeth
AU - de Kok, Theo Martinus
AU - Muller, Sara H.
AU - Peterse, Hans
AU - Tollenaar, Rob A. E. M.
AU - Hoogerbrugge, Nicoline
AU - Meijer, Sybren
AU - Bartels, Carina C. M.
AU - Seynaeve, Caroline
AU - Hooning, Maartje J.
AU - Kriege, Mieke
AU - Schmitz, Paul I. M.
AU - Oosterwijk, Jan C.
AU - de Koning, Harry J
AU - Rutgers, Emiel J. T.
AU - Klijn, Jan G. M.
PY - 2010/12/20
Y1 - 2010/12/20
N2 - The Dutch MRI Screening Study on early detection of hereditary breast cancer started in 1999. We evaluated the long-term results including separate analyses of BRCA1 and BRCA2 mutation carriers and first results on survival.Women with higher than 15% cumulative lifetime risk (CLTR) of breast cancer were screened with biannual clinical breast examination and annual mammography and magnetic resonance imaging (MRI). Participants were divided into subgroups: carriers of a gene mutation (50% to 85% CLTR) and two familial groups with high (30% to 50% CLTR) or moderate risk (15% to 30% CLTR).Our update contains 2,157 eligible women including 599 mutation carriers (median follow-up of 4.9 years from entry) with 97 primary breast cancers detected (median follow-up of 5.0 years from diagnosis). MRI sensitivity was superior to that of mammography for invasive cancer (77.4% v 35.5%; P
AB - The Dutch MRI Screening Study on early detection of hereditary breast cancer started in 1999. We evaluated the long-term results including separate analyses of BRCA1 and BRCA2 mutation carriers and first results on survival.Women with higher than 15% cumulative lifetime risk (CLTR) of breast cancer were screened with biannual clinical breast examination and annual mammography and magnetic resonance imaging (MRI). Participants were divided into subgroups: carriers of a gene mutation (50% to 85% CLTR) and two familial groups with high (30% to 50% CLTR) or moderate risk (15% to 30% CLTR).Our update contains 2,157 eligible women including 599 mutation carriers (median follow-up of 4.9 years from entry) with 97 primary breast cancers detected (median follow-up of 5.0 years from diagnosis). MRI sensitivity was superior to that of mammography for invasive cancer (77.4% v 35.5%; P
U2 - 10.1200/JCO.2009.27.2294
DO - 10.1200/JCO.2009.27.2294
M3 - Article
C2 - 21079137
SN - 0732-183X
VL - 28
SP - 5265
EP - 5273
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 36
ER -